Albany, NY -- (SBWIRE) -- 07/31/2019 -- Adrenocortical Carcinoma Market Insights, Epidemiology and Market Forecast-2028
1. Adrenocortical carcinoma is a rare malignancy, with an incidence of 0.7–2.0 cases/million habitants/year.
2. Adrenocortical carcinoma may arise in both adrenal glands, but the left adrenal is affected slightly more often.
3. A total 2,014 Adrenocortical carcinoma diagnosed cases were identified with an age-adjusted incidence of 1.02 per million populations in the US.
DelveInsight launched a new report on Adrenocortical Carcinoma Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Adrenocortical Carcinoma market report covers a descriptive overview and comprehensive insight of the Adrenocortical Carcinoma epidemiology and Adrenocortical Carcinoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Adrenocortical Carcinoma market report provides insights on the current and emerging therapies.
3. Adrenocortical Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Adrenocortical Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Adrenocortical Carcinoma market.
Request for sample pages
"The median age at diagnosis was 55 years, and more than 60% of the cases were diagnosed between 40 to 70 years of age".
Currently, the only curative approach to Adrenocortical Carcinoma is complete tumor resection. Early-stage disease is highly curable through surgical resection of the tumor by specially trained surgical oncologists. The problem is that many of Adrenocortical Carcinoma is found at advanced stages. While there is no curative Adrenocortical Carcinoma treatment available for metastatic and recurrent Adrenocortical Carcinoma, patients may get advantages from various modalities of therapy. Adrenocortical Carcinoma Medical therapy takes two forms with the inclusion of currently available chemotherapeutic agents and evolving biological therapies.
The optimal surgical approaches such as open adrenalectomy (OA) vs laparoscopic adrenalectomy (LA), lymph nodes dissection (LND) and extensive surgery to the adjacent organs are available as the choice. Supportive care may be necessary, especially for those who have had complete surgical resection of their adrenal gland, which is the form of hormone-replacement therapy. After a tumor is surgically removed, often hormone deficiency should be monitored with the use of various hormones and dosages by an endocrinologist. For advanced disease, other local modalities of Adrenocortical Carcinoma therapies may be continued in terms of improving symptoms. These modalities, including radiation therapy, radiofrequency ablation (RFA), cryotherapy, and ablative nerve techniques, may be essential to manage tumor complications of growth.
In the same way, the genetic comprehension of adrenal tumorigenesis continues to advance, more targets for future drug development are recognised and analysed. As these discoveries are practised into clinical practice, Adrenocortical Carcinoma therapy will move beyond historical modalities to the benefit of patients everywhere. Further integration of oncogenetic and molecular targets hope to deliver curative Adrenocortical Carcinoma therapies during the forecast period.
The launch of the emerging therapies is expected to significantly impact Adrenocortical Carcinoma treatment scenario in the upcoming years:-
Drugs covered
1. Exelixis
2. Millendo Therapeutics
3. Orphagen pharmaceuticals
And many others
The key players in Adrenocortical Carcinoma market are:
1. Cabozantinib
2. ATR-101
And many others
Table of contents
1. Report Introduction
2. Adrenocortical Carcinoma Market Overview at a Glance
3. Adrenocortical Carcinoma Disease Background and Overview
4. Adrenocortical Carcinoma Epidemiology and Patient Population
4.1. United States
4.2. EU-5
4.2.1 Germany
4.2.2. France
4.2.3. Italy
4.2.4. Spain
4.2.5. United Kingdom
4.3. Japan
5. Adrenocortical Carcinoma Treatments & Medical Practices
6. Adrenocortical Carcinoma Marketed Therapies
6.1. Lysodren (Mitotane): Bristol-Myers Squibb
7. Adrenocortical Carcinoma Emerging Therapies
8. Key Cross Competition
8.1. Cabozantinib: Exelixis
8.2. ATR-101: Millendo Therapeutics
9. Adrenocortical Carcinoma Market Size
10. 7MM Adrenocortical Carcinoma Country-Wise Market Analysis
11. United States Market Size
12. Germany Market Size
13. France Market Size
14. United Kingdom Market Size
15. Spain Market Size
16. Italy Market Size
17. Japan Market Size
18. Adrenocortical Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight